[The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?]

Abstract

Denosumab is an effective treatment for osteoporosis. However, an increasing number of patients are developing so-called rebound vertebral fractures, because of a considerable increase of bone resorption after cessation of denosumab therapy. The prevalence of these new vertebral fractures is still unknown. In patients with high risk of new fractures, it is recommended to consider continuing denosumab treatment, or to switch to another antiresorptive medication such as bisphosphonates.

• Authors: Bruce H R Wolffenbuttel, Elske Marije Abma, Natasha M Appelman-Dijkstra
• Journal: Nederlands tijdschrift voor geneeskunde (Ned Tijdschr Geneeskd) Vol. 162 (May 14 2018) ISSN: 1876-8784 [Electronic] Netherlands
• Vernacular Title: Het denosumab-dilemma.
• PMID: 30040306 (Publication Type: Journal Article, Review)

Chemical References

• Bone Density Conservation Agents
• Diphosphonates
• Denosumab

Topics

• Bone Density
• Bone Density Conservation Agents (adverse effects)
• Denosumab (adverse effects)
• Diphosphonates (administration & dosage)
• Female
• Fractures, Bone (chemically induced)
• Humans
• Osteoporosis (complications)
• Osteoporosis, Postmenopausal (drug therapy, physiopathology)
• Spinal Fractures (chemically induced, prevention & control)